Fuzeon is an Antiretroviral Agent, Fusion Protein Inhibitor. It inhibits the fusion of HIV-1 virus with CD4 cells by blocking the conformational change in gp41 required for membrane fusion and entry into CD4 cells.

**Pre-Authorization Criteria:** treatment of HIV-1 infection in combination with other antiretroviral agents in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

VCHCP requires that it be prescribed by an Immunology Clinic physician.

**DOSING:**

- **ADULTS — HIV Treatment:** SubQ: 90 mg twice daily

- **PEDIATRIC — HIV treatment:** SubQ: Children 6 years: 2 mg/kg twice daily (maximum dose: 90 mg twice daily).

- **ELDERLY —** See adults dosing.

- **RENAL IMPAIRMENT —** No dosage adjustment required.

**Recommended Dosing Regimen and Authorization Limit:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosing Regimen</th>
<th>Authorization Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fuzeon™ (enfuvirtide)</td>
<td>Patients 6 to 16 years old: 2 mg/kg BID up to a maximum of 90 mg BID</td>
<td>Initial authorization for 6 months, continue therapy for length of benefit with <strong>one</strong> of the following:</td>
</tr>
<tr>
<td></td>
<td>Adult: 90 mg SQ BID</td>
<td>1. Minimum 0.5 log decrease in viral load from baseline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Minimum increase of 25% in CD4+ count</td>
</tr>
</tbody>
</table>
DOSAGE FORMS — Injection, powder for reconstitution [single-use vial]: 108 mg [90 mg/mL following reconstitution; available in convenience kit of 60 vials, SWFI, syringes, alcohol wipes, patient instructions]

ADMINISTRATION — Inject subcutaneously into upper arm, abdomen, or anterior thigh. Do not inject into moles, scar tissue, bruises, or the navel. Rotate injection site, give injections at a site different from the preceding injection site; do not inject into any site where an injection site reaction is evident.

CONTRAINDICATIONS — Hypersensitivity to enfuvirtide or any component of the formulation

WARNINGS / PRECAUTIONS — Monitor closely for signs/symptoms of pneumonia; associated with an increased incidence during clinical trials, particularly in patients with a low CD4 cell count, high initial viral load, I.V. drug use, smoking, or a history of lung disease. May cause hypersensitivity reactions (symptoms may include rash, fever, nausea, vomiting, hypotension, and elevated transaminases). In addition, local injection site reactions may occur. Safety and efficacy have not been established in children <6 years of age.

DRUG INTERACTIONS — No interactions have been identified which would require alteration of other antiretroviral drugs.

PREGNANCY RISK FACTOR — B

PREGNANCY IMPLICATIONS — Teratogenic effects were not observed in animal studies, however there are no studies in pregnant women. An antiretroviral registry has been established to monitor maternal and fetal outcomes in women receiving antiretroviral drugs. Physicians are encouraged to register patients at 1-800-258-4263 or www.APRegistry.com.

LACTATION — Excretion in breast milk unknown/contraindicated

BREAST-FEEDING CONSIDERATIONS — HIV-infected mothers are discouraged from breast-feeding to decrease potential transmission of HIV.

PATIENT EDUCATION — Report any signs/symptoms of hypersensitivity or infection, including pneumonia (risk may be increased during therapy). Follow injection instructions closely. Rotate injection site, give injections at a site different from the preceding injection site; do not inject into any site where an injection site reaction is evident. Inject subcutaneously into upper arm, abdomen, or anterior thigh. Do not inject into moles, scar tissue, bruises, or the navel.
REFERENCES


2. Fuzeon internet site accessed July 11, 2005


Select Drug Information from Lexi-Comp Online™
Copyright (1978 to present) Lexi-Comp, Inc.

©2013 UpToDate® • www.uptodate.com

Epocrates 2013 – www.epocrates.com

Revision History:

Date Reviewed/Updated: 10/4/11 by A. Reeves MD
Date Reviewed/No Updates: 4/2/12; 1/16/13 by A. Reeves MD
Date Approved by P&T Committee: 7/28/05; 10/25/11; 4/24/12; 1/29/13
Date Reviewed/No Updates: P&T 1/28/14 by C. Sanders MD
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 3/12/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>Date</td>
<td>Approval</td>
<td>Name(s)</td>
<td>Event</td>
</tr>
<tr>
<td>----------</td>
<td>----------</td>
<td>-------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>